SPARC Methylation in Lung Cancer
Author Information
Author(s): Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana U G, Iizasa T, Fujisawa T, Hiroshima K, Gazdar A F
Primary Institution: University of Texas Southwestern Medical Center
Hypothesis
The study investigates the loss of SPARC expression and its correlation with promoter methylation in lung cancers.
Conclusion
SPARC is downregulated in lung cancer cells through DNA methylation, and this methylation is associated with poorer prognosis in adenocarcinomas.
Supporting Evidence
- 60% of lung cancer cell lines showed loss of SPARC expression.
- SPARC methylation was found in 69% of primary lung tumors.
- Treatment with a demethylating agent restored SPARC expression in all tested cell lines.
Takeaway
This study found that a protein called SPARC is often turned off in lung cancer cells because of a process called methylation, which can lead to worse outcomes for patients.
Methodology
The study used RT-PCR and methylation-specific PCR to analyze SPARC expression and methylation in lung cancer cell lines and primary tumors.
Limitations
The study did not find significant associations with gender, age, smoking history, or tumor stage.
Participant Demographics
Patients with lung cancer who had not received treatment prior to resection.
Statistical Information
P-Value
0.0021
Confidence Interval
1.75–12.35
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website